These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38512387)

  • 1. Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins.
    De Groote R; Lefever E; Charleer S; Donné P; Block C; Mathieu C; Gillard P
    Diabetes Technol Ther; 2024 Aug; 26(8):587-595. PubMed ID: 38512387
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.
    Takahashi H; Nishimura R; Onda Y; Ando K; Tsujino D; Utsunomiya K
    Expert Opin Pharmacother; 2017 Mar; 18(4):335-342. PubMed ID: 28234565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
    Tentolouris N; Knudsen ST; Lapolla A; Wolden ML; Haldrup S; Schultes B
    Adv Ther; 2019 May; 36(5):1201-1210. PubMed ID: 30879256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Switching to Insulin Degludec From Other Basal Insulins in Adult Patients With Type 1 or Type 2 Diabetes.
    Baran O; Dersch-Mills D; Bakal JA; Huyghebaert T; Hnatiuk M; Roedler RL
    Can J Diabetes; 2022 Jun; 46(4):381-387.e4. PubMed ID: 35490094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
    Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
    Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study.
    Danne T; Axel Schweitzer M; Keuthage W; Kipper S; Kretzschmar Y; Simon J; Wiedenmann T; Ziegler R
    Diabetes Technol Ther; 2021 Mar; 23(3):203-212. PubMed ID: 32924568
    [No Abstract]   [Full Text] [Related]  

  • 10. The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.
    Visser MM; Charleer S; Fieuws S; De Block C; Hilbrands R; Van Huffel L; Maes T; Vanhaverbeke G; Dirinck E; Myngheer N; Vercammen C; Nobels F; Keymeulen B; Mathieu C; Gillard P
    J Diabetes Sci Technol; 2024 May; 18(3):660-666. PubMed ID: 36172693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting.
    Danne TPA; Joubert M; Hartvig NV; Kaas A; Knudsen NN; Mader JK
    Diabetes Care; 2024 Jun; 47(6):995-1003. PubMed ID: 38569055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
    Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
    Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
    Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
    Siegmund T; Tentolouris N; Knudsen ST; Lapolla A; Prager R; Phan TM; Wolden ML; Schultes B;
    Diabetes Obes Metab; 2018 Mar; 20(3):689-697. PubMed ID: 29106039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.
    Martens T; Beck RW; Bailey R; Ruedy KJ; Calhoun P; Peters AL; Pop-Busui R; Philis-Tsimikas A; Bao S; Umpierrez G; Davis G; Kruger D; Bhargava A; Young L; McGill JB; Aleppo G; Nguyen QT; Orozco I; Biggs W; Lucas KJ; Polonsky WH; Buse JB; Price D; Bergenstal RM;
    JAMA; 2021 Jun; 325(22):2262-2272. PubMed ID: 34077499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
    Haldrup S; Lapolla A; Gundgaard J; Wolden ML
    J Med Econ; 2020 Mar; 23(3):271-279. PubMed ID: 31526202
    [No Abstract]   [Full Text] [Related]  

  • 18. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry.
    Sandig D; Grimsmann J; Reinauer C; Melmer A; Zimny S; Müller-Korbsch M; Forestier N; Zeyfang A; Bramlage P; Danne T; Meissner T; Holl RW
    Diabetes Technol Ther; 2020 Aug; 22(8):602-612. PubMed ID: 32522039
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.